Usefulness of contrast-enhanced ultrasonography in determining treatment efficacy and outcome after pancreatic cancer chemotherapy

Figure 1 Enhancement pattern of CE-US in pancreatic cancer. A-C: Vascular image; D-F: Perfusion image; A, D: Hypovascularity; B, E: Isovascularity; C, F: Hypervascularity.

Figure 2 CE-US changes over time in the R (HI) group (luminance score). A: B-mode; B: Pre (0.30); C: Post 2 course (0.28); D: Post 4 course (0.78); E: Post 7 course (0.62); F: Post 16 course (0.46).

Figure 3 CT changes over time in the R (HH) group. A: Pre; B: Post 4 course; C: Post 7 course; D: Post 16 course.

Figure 4 CE-US changes over time in the R (II) group (luminance score). A: B-mode; B: Pre (0.96); C: Post 2 course (0.99); D: Post 4 course (1.0); E: Post 7 course (0.93); F: Post 11 course (1.0).

Figure 5 CT changes over time in the R (II) group. A: Pre; B: Post 2 course; C: Post 7 course; D: Post 11 course.

Figure 6 CE-US changes over time in the P (HH) group (luminance score). A: B-mode; B: Pre (0.29); C: Post 2 course (0.46); D: Post 3 course (0.29).

Figure 7 CT changes over time in the P (HH) group. A: pre; B: post 3 course.

Figure 8 Histological change of post-treatment tissue biopsy pre-chemotherapy (A) and post-chemotherapy (B).

Figure 9 Kaplan-Meier survival curves by enhancement pattern of CE-US and outcome after chemotherapy.